<DOC>
	<DOC>NCT02250495</DOC>
	<brief_summary>The purpose of the VIBE study is to evaluate the efficacy and safety of the Sympara Therapeutic System in the treatment of hypertension</brief_summary>
	<brief_title>The Sympara VIBE Study for Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<criteria>Office systolic blood pressure of ≥150mmHg based on an average of three (3) blood pressure reading measured at both the initial screening visit and a confirmatory screening visit OR a mean daytime systolic blood pressure ≥135mm Hg on 24hour Ambulatory Blood Pressure Measurement Receiving and adhering to an appropriate antihypertensive treatment regimen, as prescribed by physician Minimum six (6) month history of diagnosis and treatment of hypertension Previous renal denervation or carotid barostimulation implant Secondary causes of hypertension or primary pulmonary hypertension Prior surgery or radiation to the area of the carotid sinus, or presence of a stent or other implant in the carotid artery Known or suspected baroreflex failure or significant orthostatic hypotension One or more hospital admissions for a hypertensive crisis within the past year History of myocardial infarction, fibrillation event, unstable angina pectoris, syncope, transient ischemic attach (TIA) or a cerebrovascular accident within six (6) months of the screening period, or has widespread atherosclerosis with documented intrasvascular thrombosis or unstable plaques Diabetes mellitus (Type 1) Chronic renal disease requiring dialysis Kidney or liver transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>